DMK Pharmaceuticals Corporation

OTCPK:DMKP.Q 株式レポート

時価総額：US$302.8k

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

DMK Pharmaceuticals マネジメント

マネジメント 基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Eddie Glover

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間no data
CEOの所有権n/a
経営陣の平均在職期間データなし
取締役会の平均在任期間2.8yrs

経営陣の近況

Recent updates

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Sep 30

Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

Jul 29

Adamis CEO urges stock split approval, slate of directors in letter to shareholders

Jul 21

Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope

Apr 13

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Jan 20

Adamis Pharmaceuticals: It's Now Or Never

Dec 02

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Sep 03

Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

Jun 13

Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19

Jun 07

Adamis pharmaceuticals gets deficiency letter from NASDAQ

May 28

Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering

Jan 29

Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose

Nov 16

Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue

Nov 09

CEO（最高経営責任者

Eddie Glover (74 yo)

no data

在職期間

Mr. Eddie Wabern Glover serves as Chief Executive Officer of US Compounding Inc at DMK Pharmaceuticals Corporation (formerly known as Adamis Pharmaceuticals Corporation). He co-founded US Compounding, Inc....

取締役

名称ポジション在職期間報酬所有権
Howard Birndorf
Independent Director4.9yrsUS$64.00k0%
$ 0
Vickie Reed
Independent Director2.2yrsUS$47.18kデータなし
Meera Desai
Independent Director2.8yrsUS$64.00kデータなし

2.8yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: DMKP.Qの 取締役会 は 経験豊富 ではない ( 2.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。